“Despite the important role the PI3K/mTOR pathway plays in tumor types such as breast and prostate cancer, the available therapies that target this pathway have only reported limited improvements in outcomes for patients. Development of an optimized PI3K/mTOR inhibitor, like gedatolisib, thus represents, we believe, one of the most important opportunities to improve the standard of care in these cancers. With our Phase 3 program in HR+/HER2- advanced breast cancer, and our newly initiated Phase 1b/2 program in metastatic castration resistance prostate cancer, we are hoping to eventually impact over 200,000 patients globally,” said Brian Sullivan, CEO. “The equity financing we recently closed further supports these programs and extends our cash runway into mid-2026.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CELC:
- Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- CELC Earnings this Week: How Will it Perform?
- Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
- Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
- Celcuity announces $50M private placement